Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts 02114.
Cutaneous Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114; email:
Annu Rev Pathol. 2017 Jan 24;12:75-102. doi: 10.1146/annurev-pathol-052016-100208. Epub 2016 Dec 5.
Melanoma is a complex and genomically diverse malignancy, and new genes and signaling pathways involved in pathogenesis continue to be discovered. Mechanistic insights into gene and immune regulation in melanoma have led to the development of numerous successful and innovative pharmacologic agents over recent years. Multiple targeted therapies and immunotherapies have already entered the clinic, becoming new standards of care and transforming the prognosis for many patients with malignant melanoma. In this review, we provide an overview of the current understanding of signaling and immune regulation in melanoma and implications for responses to treatment, organized in the framework of hallmark characteristics in cancer.
黑色素瘤是一种复杂且具有基因组多样性的恶性肿瘤,新的基因和参与发病机制的信号通路不断被发现。对黑色素瘤中基因和免疫调节的机制研究,导致近年来开发出许多成功和创新的药物。多种靶向治疗和免疫疗法已经进入临床,成为新的治疗标准,改变了许多恶性黑色素瘤患者的预后。在这篇综述中,我们提供了对黑色素瘤中信号和免疫调节的当前认识的概述,并探讨了这些认识对治疗反应的影响,组织在癌症的标志性特征框架内。